Advertisement

More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

Published:November 19, 2022DOI:https://doi.org/10.1016/j.dld.2022.11.004
      With great interest, we read a systemic review and meta-analysis by Attauabi et al. [
      • Attauabi M.
      • Madsen G.R.
      • Bendtsen F.
      • et al.
      Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis.
      ], suggesting that vedolizumab has a favorable efficacy and safety profile in bio-naïve patients with ulcerative colitis (UC) and Crohn's disease than bio-exposed patients. Vedolizumab is a highly safe biologic that selectively acts in the intestinal tract; thus, systemic side reactions are considered unlikely [
      • Qiu B.
      • Liang J.X.
      • Li C.
      Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
      ]. Patients at higher risk for serious infections, such as children, the elderly, or patients with chronic lung disease, may benefit more from vedolizumab treatment than from immunosuppressants, corticosteroids, or tumor necrosis factor-α (TNF-α) antagonists [
      • Mosli M.H.
      • MacDonald J.K.
      • Bickston S.J.
      • et al.
      Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Attauabi M.
        • Madsen G.R.
        • Bendtsen F.
        • et al.
        Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis.
        Dig Liver Dis. 2022; 54: 1168-1178
        • Qiu B.
        • Liang J.X.
        • Li C.
        Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
        Medicine. 2022; 101: e30590
        • Mosli M.H.
        • MacDonald J.K.
        • Bickston S.J.
        • et al.
        Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
        Inflamm Bowel Dis. 2015; 21: 1151-1159
        • Kakiuchi T.
        • Yoshiura M.
        Vedolizumab as the first-line of BioLogicals for pediatric patients with ulcerative colitis.
        Clin Ther. 2022; 44: 1028-1032
        • Turner D.
        • Ruemmele F.M.
        • Orlanski-Meyer E.
        • et al.
        Management of paediatric ulcerative colitis, Part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, hepatology and nutrition.
        J Pediatr Gastroenterol Nutr. 2018; 67: 257-291
        • Kamm M.A.
        • Hanauer S.B.
        • Panaccione R.
        • et al.
        Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
        Aliment Pharmacol Ther. 2011; 34: 306-317
        • Faleck D.M.
        • Winters A.
        • Chablaney S.
        • et al.
        Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn's disease but not ulcerative colitis.
        Clin Gastroenterol Hepatol. 2019; 17 (e1): 2497-2505
        • Shimodaira Y.
        • Watanabe K.
        • Iijima K.
        Clinical course of ulcerative colitis associated with an age at diagnosis: a recent Japanese database survey.
        Tohoku J Exp Med. 2021; 255: 33-39

      Linked Article